Imunon (NASDAQ:IMNN) Trading Down 2.3%

Shares of Imunon, Inc. (NASDAQ:IMNN) were down 2.3% during mid-day trading on Wednesday . The company traded as low as $1.28 and last traded at $1.30. Approximately 32,389 shares were traded during trading, a decline of 83% from the average daily volume of 186,613 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on Imunon from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, April 1st.

Imunon Price Performance

The company has a market cap of $12.22 million, a PE ratio of -0.60 and a beta of 2.03. The firm has a 50-day simple moving average of $1.09 and a two-hundred day simple moving average of $0.90.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.07. Equities research analysts forecast that Imunon, Inc. will post -2.27 EPS for the current year.

Imunon Company Profile

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.